Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

In a shift away from GMOS, aka genetically modified organisms, important research is continuing in gene editing, sometimes ...

Scientists in the polo-obsessed nation have produced world's first genetically edited horses, designed to outrun champion ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...